4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol | 847605-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol
• 英文别名: 4-{[4-(aminomethyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-ol；2H-Pyran-4-ol, 4-[[4-(aminomethyl)-1-piperidinyl]methyl]tetrahydro-；4-[[4-(aminomethyl)piperidin-1-yl]methyl]oxan-4-ol
• CAS: 847605-31-6
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.335
• InChiKey: FCQCQQKTIAAYCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol 、 6-fluoro-1-isopropyl-1,3-dihydro-2H-benzo[d]imidazol-2(3H)-one 在 对硝基苯基氯甲酸酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以79%的产率得到5-fluoro-N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
  参考文献：
  名称：

  [EN] BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY
  [FR] COMPOSES DE BENZIMIDAZOLONE A ACTIVITE D'AGONISTES DU RECEPTEUR 5-HT4

  摘要：

  该发明提供了式(I)的化合物或其药用可接受的盐，以及含有这种化合物的组合物和利用这种化合物制造用于治疗胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动活性，因此对于治疗哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。

  公开号：

  WO2005021539A1
• 作为产物：
  描述：

  1-[(4-羟基四氢-2H-吡喃-4-基)甲基]哌啶-4-甲酰胺 在 sodium tetrahydroborate 、 溶剂黄146 、 盐酸 、 水 、 sodium hydroxide 作用下， 以 三甘醇二甲醚 、 水 为溶剂， 反应 1.0h， 生成 4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol
  参考文献：
  名称：

  [EN] BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY
  [FR] COMPOSES DE BENZIMIDAZOLONE A ACTIVITE D'AGONISTES DU RECEPTEUR 5-HT4

  摘要：

  该发明提供了式(I)的化合物或其药用可接受的盐，以及含有这种化合物的组合物和利用这种化合物制造用于治疗胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动活性，因此对于治疗哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。

  公开号：

  WO2005021539A1
• 作为试剂：
  描述：

  4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol 、 4-nitrophenyl 6-fluoro-3,3-dimethyl-2-oxo-2,3-dihydroindole-1-carboxylate 在 4-{ [4-(aminomethyl) piperidin-1-yl] methy} tetrahydro-2-pyran-4-ol 作用下， 以69的产率得到Pf-03382792
  参考文献：
  名称：

  J. Med. Chem. 2008, 51, 1861-1873

  摘要：

  DOI：

文献信息

• [EN] QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY<br/>[FR] COMPOSES D'ACIDE QUINOLONECARBOXYLIQUE A ACTIVITE AGONISTE DU RECEPTEUR 5-HT4
  申请人：PFIZER JAPAN INC

  公开号：WO2005049608A1

  公开（公告）日：2005-06-02

  This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents α1;A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; Rl represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1, 2 or 3, or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  该发明提供了一种化合物，其化学式为（I）：其中Het代表含有一个氮原子的杂环基团，其中B直接结合，含有从4到7个碳原子，该杂环基团未取代或者取代1到4个独立选择自α1取代基的取代基；A代表含有从1到4个碳原子的烷基基团；B代表共价键或含有从1到5个碳原子的烷基基团；R1代表异丙基基团、正丙基基团或环戊基团；R2代表甲基基团、氟原子或氯原子；R3独立代表（i）酮基、羟基、氨基、烷基氨基或羧基；（ii）含有从3到8个碳原子的环烷基团，该环烷基团被1到5个取代基取代；或（iii）含有从3到8个原子的杂环基团，该杂环基团未取代或者取代1到5个取代基，n为1、2或3，或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。
• [EN] 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY<br/>[FR] DERIVES DE 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE PRESENTANT UNE ACTIVITE AGONISTE DU RECEPTEUR5-HT4
  申请人：PFIZER JAPAN INC

  公开号：WO2005073222A1

  公开（公告）日：2005-08-11

  This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula -C(R4)(R5)- (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  该发明提供了一个化合物，其化学式为(I)：其中R1代表具有1到4个碳原子的烷基基团或卤素原子，R2代表具有1到4个碳原子的烷基基团，R3代表氢原子或羟基团，A代表氧原子或具有化学式-C(R4)(R5)-的基团（其中R4代表氢原子或具有1到4个碳原子的烷基基团，R5代表羟基或具有1到4个碳原子的烷氧基）或其药用可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于治疗哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。
• [EN] 4-AMINO-5-HALOGENO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, CNS, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS<br/>[FR] DERIVES DE 4-AMINO-5-HALOGENO-BENZAMIDE UTILES COMME AGONISTES DU RECEPTEUR 5-HT4 DANS LE TRAITEMENT DES TROUBLES GASTRO-INTESTINAUX, DU SYSTEME NERVEUX CENTRAL, NEUROLOGIQUES ET CARDIO-VASCULAIRES
  申请人：PFIZER JAPAN INC

  公开号：WO2005092882A1

  公开（公告）日：2005-10-06

  This invention provides a compound of the formula (I): wherein Rl represents a halogen atom; R2 represents a hydrogen atom etc.; R3 represents an alkyl group having from 1 to 4 carbon atoms etc.;R4 represents a hydrogen atom, a hydroxy group, a carboxy group etc.; A represents an oxygen atom etc. or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了公式（I）的化合物：其中R1代表卤素原子；R2代表氢原子等；R3代表具有1至4个碳原子的烷基等；R4代表氢原子、羟基、羧基等；A代表氧原子等或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病的治疗有用。
• Benzimidazolone compounds having 5-HT4 receptor agonistic activity
  申请人：Katsu Yasuhiro

  公开号：US20050148573A1

  公开（公告）日：2005-07-07

  This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了一种式（I）的化合物或其药学上可接受的盐，并且还提供了包含这种化合物的组合物以及使用这种化合物制造治疗胃食管反流病、胃肠道疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动作用，因此对于哺乳动物，特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。
• Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity
  申请人：Kato Tomoki

  公开号：US20080255113A1

  公开（公告）日：2008-10-16

  This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents α 1 ; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R 1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R 2 represents a methyl group, a fluorine atom or a chlorine atom; R 3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1, 2 or 3, or a pharmaceutically acceptable salts thereof. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了式（I）的化合物：其中，Het代表具有一个氮原子的杂环基团，与B直接结合，具有4至7个碳原子，所述杂环基团未被取代或被1至4个取代基独立地选自α1取代基组成的基团取代；A代表具有1至4个碳原子的脂肪族基团；B代表共价键或具有1至5个碳原子的脂肪族基团；R1代表异丙基基团、正丙基基团或环戊基团；R2代表甲基基团、氟原子或氯原子；R3独立地代表（i）氧代基、羟基、氨基、烷基氨基或羧基；（ii）具有3至8个碳原子的环烷基团，所述环烷基团被1至5个取代基取代；或（iii）具有3至8个原子的杂环基团，所述杂环基团未被取代或被1至5个取代基独立地选自α1取代基组成的基团取代，n为1、2或3，或其药学上可接受的盐。这些化合物具有5-HT4受体激动活性，因此对于哺乳动物，特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。